Blueprint Medicines (BPMC) Tops Q3 EPS by $3.50

Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of $11.16, $3.50 better than the analyst estimate of $7.66. Revenue for the quarter came in at $745.1 million versus the consensus estimate of $628.68 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Alphabet slides over 6% as AI brain drain and SpaceX slump converge
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating